

Georgia D Tomaras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1473838/publications.pdf>

Version: 2024-02-01

292
papers

23,060
citations

9254

74
h-index

10724

138
g-index

300
all docs

300
docs citations

300
times ranked

14844
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7552-7557.	3.3	1,708
2	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	13.9	1,699
3	The immune response during acute HIV-1 infection: clues for vaccine development. <i>Nature Reviews Immunology</i> , 2010, 10, 11-23.	10.6	707
4	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	1.5	548
5	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	13.9	518
6	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	5.8	412
7	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. <i>Journal of Virology</i> , 2011, 85, 9998-10009.	1.5	393
8	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018, 561, 479-484.	13.7	392
9	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	6.6	374
10	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9019-9024.	3.3	371
11	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. <i>Journal of Virology</i> , 2012, 86, 11521-11532.	1.5	357
12	Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. <i>Journal of Virology</i> , 2008, 82, 11651-11668.	1.5	337
13	CXCL13 is a plasma biomarker of germinal center activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2702-2707.	3.3	322
14	CD4 T follicular helper cell dynamics during SIV infection. <i>Journal of Clinical Investigation</i> , 2012, 122, 3281-3294.	3.9	307
15	Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. <i>Aids</i> , 2009, 23, 897-906.	1.0	305
16	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243.	6.3	269
17	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87572.	1.1	248
18	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015, 33, 610-616.	9.4	232

#	ARTICLE	IF	CITATIONS
19	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. <i>Science</i> , 2021, 374, 472-478.	6.0	228
20	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e75665.	1.1	214
21	An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum. <i>Journal of Virology</i> , 2011, 85, 7029-7036.	1.5	210
22	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. <i>Journal of Experimental Medicine</i> , 2011, 208, 2237-2249.	4.2	198
23	High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediated antibody responses. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2011, 79A, 603-612.	1.1	197
24	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	15.2	197
25	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018, 24, 1701-1707.	15.2	195
26	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1444-1457.	0.5	191
27	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	6.0	191
28	Immune correlates of vaccine protection against HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 310rv7.	5.8	179
29	Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. <i>Journal of Virology</i> , 2009, 83, 8925-8937.	1.5	170
30	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	3.3	170
31	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	1.5	169
32	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 11502-11519.	1.5	168
33	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDS VAX HIV-1 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e53629.	1.1	165
34	T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. <i>JCI Insight</i> , 2017, 2, .	2.3	164
35	Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design. <i>Journal of Virology</i> , 2012, 86, 4688-4692.	1.5	159
36	H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination. <i>PLoS ONE</i> , 2011, 6, e25797.	1.1	158

#	ARTICLE	IF	CITATIONS
37	Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. <i>Journal of Infectious Diseases</i> , 2011, 203, 610-619.	1.9	151
38	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	2.1	145
39	Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection. <i>PLoS Medicine</i> , 2009, 6, e1000107.	3.9	143
40	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	13.7	140
41	Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. <i>Journal of Infectious Diseases</i> , 2015, 211, 947-955.	1.9	140
42	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	5.8	137
43	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. <i>PLoS ONE</i> , 2011, 6, e23532.	1.1	137
44	HIV-1-specific antibody responses during acute and chronic HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 373-379.	1.5	135
45	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225.	1.1	131
46	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV _{mac251} Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. <i>Journal of Virology</i> , 2013, 87, 1708-1719.	1.5	130
47	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. <i>Nature Medicine</i> , 2018, 24, 1590-1598.	15.2	129
48	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. <i>Journal of Virology</i> , 2012, 86, 7588-7595.	1.5	123
49	Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys. <i>Journal of Virology</i> , 2010, 84, 10406-10412.	1.5	120
50	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. <i>PLoS Pathogens</i> , 2016, 12, e1005817.	2.1	119
51	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	5.6	119
52	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. <i>Journal of Virology</i> , 2010, 84, 4998-5006.	1.5	110
53	Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection. <i>Journal of Virology</i> , 2008, 82, 115-125.	1.5	108
54	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. <i>Cell Host and Microbe</i> , 2014, 16, 215-226.	5.1	105

#	ARTICLE	IF	CITATIONS
55	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. <i>Frontiers in Immunology</i> , 2014, 5, 170.	2.2	104
56	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	3.9	104
57	Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 203-212.	0.9	101
58	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	3.9	99
59	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. <i>Journal of Virology</i> , 2013, 87, 1554-1568.	1.5	97
60	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	2.9	97
61	Complex immune correlates of protection in HIV-1 vaccine efficacy trials. <i>Immunological Reviews</i> , 2017, 275, 245-261.	2.8	95
62	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	3.9	95
63	In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth. <i>Journal of Virology</i> , 2009, 83, 3617-3625.	1.5	94
64	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. <i>Journal of Clinical Investigation</i> , 2014, 124, 1835-1843.	3.9	93
65	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. <i>PLoS Pathogens</i> , 2011, 7, e1001273.	2.1	90
66	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. <i>Blood Advances</i> , 2017, 1, 2329-2342.	2.5	90
67	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. <i>Science Immunology</i> , 2020, 5, .	5.6	90
68	HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies. <i>Journal of Virology</i> , 2011, 85, 9555-9567.	1.5	86
69	Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016, 8, 336ra62.	5.8	86
70	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	2.1	86
71	Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. <i>Vaccine</i> , 2007, 25, 510-518.	1.7	85
72	Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk. <i>Cell</i> , 2017, 169, 72-84.e13.	13.5	83

#	ARTICLE	IF	CITATIONS
73	Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies. <i>PLoS Pathogens</i> , 2011, 7, e1002200.	2.1	82
74	Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies. <i>Journal of Virology</i> , 2011, 85, 11401-11408.	1.5	80
75	Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2014, 88, 3329-3339.	1.5	80
76	Multiple HIV-1-specific IgG3 responses decline during acute HIV-1. <i>Aids</i> , 2011, 25, 2089-2097.	1.0	79
77	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. <i>Cell</i> , 2018, 175, 387-399.e17.	13.5	78
78	HIV-1 gp120 Vaccine Induces Affinity Maturation in both New and Persistent Antibody Clonal Lineages. <i>Journal of Virology</i> , 2012, 86, 7496-7507.	1.5	76
79	Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41. <i>PLoS ONE</i> , 2011, 6, e27824.	1.1	75
80	Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during Chronic HIV Infection. <i>Journal of Immunology</i> , 2015, 195, 5625-5636.	0.4	74
81	Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2014, 210, 99-110.	1.9	73
82	A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. <i>Journal of Infectious Diseases</i> , 2011, 203, 1165-1173.	1.9	71
83	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2975-2980.	3.3	71
84	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	2.9	69
85	HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection. <i>Journal of Immunology</i> , 2009, 183, 2708-2717.	0.4	67
86	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
87	Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies. <i>Frontiers in Immunology</i> , 2017, 8, 1407.	2.2	66
88	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	6.6	65
89	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2018, 24, 847-856.	15.2	65
90	CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection. <i>Journal of Immunology</i> , 2012, 188, 4289-4296.	0.4	63

#	ARTICLE	IF	CITATIONS
91	Progress in HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 3-10.	1.5	62
92	HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. <i>Trends in Microbiology</i> , 2012, 20, 532-539.	3.5	61
93	HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. <i>Nature Communications</i> , 2019, 10, 798.	5.8	61
94	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. <i>Journal of Virology</i> , 2013, 87, 7828-7836.	1.5	59
95	First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv082.	0.4	58
96	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019, 14, e0219142.	1.1	58
97	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , 2020, 7, e688-e698.	2.1	58
98	Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5972-5977.	3.3	57
99	Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses. <i>Journal of Infectious Diseases</i> , 2015, 211, 508-517.	1.9	57
100	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1255-1263.	1.9	57
101	Dynamic Antibody Specificities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection. <i>Journal of Virology</i> , 2011, 85, 11196-11207.	1.5	56
102	Initial HIV-1 Antigen-Specific CD8 ⁺ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication. <i>Journal of Virology</i> , 2012, 86, 6835-6846.	1.5	56
103	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. <i>Cell Host and Microbe</i> , 2019, 26, 623-637.e8.	5.1	56
104	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. <i>Journal of Virology</i> , 2014, 88, 8242-8255.	1.5	55
105	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. <i>Journal of Virology</i> , 2015, 89, 9952-9961.	1.5	55
106	HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable. <i>Journal of Immunology</i> , 2011, 187, 3391-3401.	0.4	54
107	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. <i>Journal of Virology</i> , 2011, 85, 7719-7729.	1.5	54
108	CD8+T-cell-mediated control of HIV-1 and SIV infection. <i>Immunologic Research</i> , 2011, 49, 135-146.	1.3	53

#	ARTICLE	IF	CITATIONS
109	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	5.6	53
110	A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. <i>EClinicalMedicine</i> , 2020, 21, 100313.	3.2	52
111	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β -chemokines. <i>Journal of Experimental Medicine</i> , 2010, 207, 763-776.	4.2	51
112	Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 823-834.	21.5	51
113	Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. <i>PLoS Pathogens</i> , 2020, 16, e1008083.	2.1	50
114	HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. <i>Aids</i> , 2006, 20, 1481-1489.	1.0	49
115	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	5.8	47
116	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	2.7	47
117	Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). <i>PLoS ONE</i> , 2010, 5, e13579.	1.1	47
118	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	1.5	46
119	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	46
120	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	2.9	46
121	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	1.5	45
122	Vi-specific serological correlates of protection for typhoid fever. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	45
123	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	15.2	44
124	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e737-e749.	2.1	43
125	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	2.9	43
126	DNA and Protein Co-Immune Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques. <i>PLoS ONE</i> , 2014, 9, e91550.	1.1	42

#	ARTICLE	IF	CITATIONS
127	Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses. <i>PLoS Pathogens</i> , 2015, 11, e1004658.	2.1	42
128	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8643-8650.	1.5	42
129	Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. <i>Vaccines</i> , 2014, 2, 15-35.	2.1	41
130	Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity. <i>Journal of Virology</i> , 2014, 88, 5165-5170.	1.5	41
131	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	3.7	41
132	IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. <i>Frontiers in Immunology</i> , 2019, 10, 2582.	2.2	40
133	Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial. <i>PLoS ONE</i> , 2011, 6, e24517.	1.1	39
134	Novel directions in HIV-1 vaccines revealed from clinical trials. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 421-431.	1.5	39
135	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	39
136	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39
137	Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk. <i>Journal of Virology</i> , 2013, 87, 6986-6999.	1.5	38
138	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017, 13, e1006182.	2.1	38
139	B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. <i>Trends in Molecular Medicine</i> , 2011, 17, 108-116.	3.5	37
140	IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. <i>PLoS ONE</i> , 2014, 9, e90725.	1.1	37
141	Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. <i>PLoS ONE</i> , 2016, 11, e0152038.	1.1	37
142	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. <i>Journal of Virology</i> , 2019, 93, .	1.5	37
143	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. <i>PLoS Pathogens</i> , 2020, 16, e1008764.	2.1	37
144	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. <i>PLoS ONE</i> , 2014, 9, e101863.	1.1	36

#	ARTICLE	IF	CITATIONS
145	HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. <i>Journal of Virology</i> , 2018, 92, .	1.5	36
146	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8525-8539.	1.5	35
147	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	5.8	35
148	Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. <i>Vaccine</i> , 2015, 33, 2347-2353.	1.7	34
149	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <i>Journal of Immunology</i> , 2016, 197, 2726-2737.	0.4	34
150	Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2016, 90, 8842-8854.	1.5	34
151	Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. <i>Virology</i> , 2010, 396, 339-348.	1.1	33
152	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 ⁺ T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , 2017, 24, .	3.2	33
153	Alterations of the B-Cell Response by HIV-1 Replication. <i>Current HIV/AIDS Reports</i> , 2011, 8, 23-30.	1.1	32
154	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	1.9	32
155	Strategies for eliciting HIV-1 inhibitory antibodies. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 421-427.	1.5	31
156	CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection. <i>Journal of Virology</i> , 2015, 89, 4690-4695.	1.5	31
157	Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum. <i>PLoS ONE</i> , 2012, 7, e37648.	1.1	30
158	A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	30
159	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326.	0.4	30
160	Impact of T _H 1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	30
161	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	29
162	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , 2017, 12, e0179597.	1.1	29

#	ARTICLE	IF	CITATIONS
163	Secretion of MIP-1 β and MIP-1 α by CD8 $^+$ T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. <i>Cellular Immunology</i> , 2011, 266, 154-164.	1.4	28
164	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550.	1.9	28
165	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018, 14, e1006986.	2.1	28
166	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. <i>Journal of Clinical Investigation</i> , 2019, 129, 1314-1328.	3.9	28
167	Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. <i>Journal of Virology</i> , 2017, 91, .	1.5	27
168	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019, 10, 863.	5.8	27
169	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	3.9	27
170	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. <i>Journal of Clinical Investigation</i> , 2019, 129, 4769-4785.	3.9	27
171	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	1.1	27
172	Aggregate complexes of HIV-1 induced by multimeric antibodies. <i>Retrovirology</i> , 2014, 11, 78.	0.9	26
173	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	1.5	26
174	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	2.0	26
175	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	1.5	26
176	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	2.2	25
177	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	1.5	25
178	In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against <i>Plasmodium falciparum</i> circumsporozoite protein (CSP). <i>Scientific Reports</i> , 2021, 11, 5318.	1.6	25
179	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , 2020, 5, .	2.3	25
180	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 4843-4856.	3.9	25

#	ARTICLE	IF	CITATIONS
181	ETS transcription factors regulate an enhancer activity in the third intron of TNF- α . <i>Journal of Leukocyte Biology</i> , 1999, 66, 183-193.	1.5	24
182	Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. <i>Vaccine Journal</i> , 2016, 23, 496-506.	3.2	24
183	Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects. <i>Journal of Infectious Diseases</i> , 2011, 204, 1541-1549.	1.9	23
184	Innate Activation of MDC and NK Cells in High-Risk HIV-1-Exposed Seronegative IV-Drug Users Who Share Needles When Compared With Low-Risk Nonsharing IV-Drug User Controls. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 68, 264-273.	0.9	23
185	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016, 90, 4951-4965.	1.5	23
186	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
187	Transcriptional and Posttranscriptional Regulation of Cytokine Gene Expression in HIV-1 Antigen-Specific CD8 ⁺ T Cells That Mediate Virus Inhibition. <i>Journal of Virology</i> , 2014, 88, 9514-9528.	1.5	22
188	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	1.5	22
189	Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. <i>Journal of Infectious Diseases</i> , 2017, 215, S152-S159.	1.9	22
190	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020, 30, 1553-1569.e6.	2.9	21
191	Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques. <i>Vaccine</i> , 2017, 35, 639-646.	1.7	20
192	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	20
193	Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
194	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. <i>Frontiers in Immunology</i> , 2019, 10, 2875.	2.2	20
195	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. <i>PLoS ONE</i> , 2019, 14, e0225622.	1.1	20
196	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021, 22, 1294-1305.	7.0	20
197	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. <i>PLoS ONE</i> , 2016, 11, e0153484.	1.1	20
198	Mechanisms for HIV-1 entry: Current strategies to interfere with this step. <i>Current Infectious Disease Reports</i> , 2001, 3, 93-99.	1.3	19

#	ARTICLE	IF	CITATIONS
199	Tat-SF1 Is Not Required for Tat Transactivation but Does Regulate the Relative Levels of Unspliced and Spliced HIV-1 RNAs. <i>PLoS ONE</i> , 2009, 4, e5710.	1.1	19
200	A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. <i>Journal of Immunological Methods</i> , 2013, 395, 1-13.	0.6	19
201	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. <i>Journal of Virology</i> , 2017, 91, .	1.5	19
202	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. <i>PLoS Pathogens</i> , 2019, 15, e1008121.	2.1	19
203	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020, 94, .	1.5	19
204	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	2.1	19
205	Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. <i>Aids</i> , 2016, 30, 1005-1014.	1.0	18
206	Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. <i>Journal of Infectious Diseases</i> , 2016, 213, 156-164.	1.9	18
207	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 859-868.	0.5	18
208	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 436-447.	1.1	18
209	HIV vaccine delayed boosting increases Env variable region 1-specific antibody effector functions. <i>JCI Insight</i> , 2020, 5, .	2.3	18
210	HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A33-A34.	0.5	17
211	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. <i>Journal of AIDS & Clinical Research</i> , 2015, 06, .	0.5	17
212	Antibody Fab properties outperform titer in predictive models of SIV vaccine-induced protection. <i>Molecular Systems Biology</i> , 2019, 15, e8747.	3.2	17
213	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	1.6	17
214	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
215	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. <i>Journal of Virology</i> , 2014, 88, 9406-9417.	1.5	16
216	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. <i>IScience</i> , 2021, 24, 102047.	1.9	16

#	ARTICLE	IF	CITATIONS
217	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016, 11, e0161753.	1.1	16
218	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	1.1	16
219	Epigenetic regulation of CD8+ T-lymphocyte mediated suppression of HIV-1 replication. <i>Virology</i> , 2010, 405, 234-242.	1.1	15
220	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	2.9	15
221	Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. <i>Journal of Infectious Diseases</i> , 2016, 213, 1946-1954.	1.9	14
222	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016, 17, 57-65.	2.6	14
223	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. <i>PLoS ONE</i> , 2018, 13, e0194266.	1.1	14
224	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. <i>PLoS Pathogens</i> , 2020, 16, e1008377.	2.1	14
225	CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I. <i>Frontiers in Bioscience - Landmark</i> , 2001, 6, d575.	3.0	13
226	Lack of B Cell Dysfunction Is Associated with Functional, gp120-Dominant Antibody Responses in Breast Milk of Simian Immunodeficiency Virus-Infected African Green Monkeys. <i>Journal of Virology</i> , 2013, 87, 11121-11134.	1.5	13
227	Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques. <i>Vaccine Journal</i> , 2014, 21, 1385-1395.	3.2	13
228	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. <i>Journal of Virology</i> , 2016, 90, 8644-8660.	1.5	13
229	Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. <i>Frontiers in Microbiology</i> , 2018, 9, 1326.	1.5	13
230	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
231	Vaccination with Vaxfectin [®] adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 viremia. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2069-2080.	1.4	12
232	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. <i>Journal of Virology</i> , 2016, 90, 5315-5328.	1.5	12
233	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017, 12, e0176428.	1.1	12
234	Bringing the path toward an HIV-1 vaccine into focus. <i>PLoS Pathogens</i> , 2020, 16, e1008663.	2.1	12

#	ARTICLE	IF	CITATIONS
235	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. <i>ELife</i> , 2021, 10, .	2.8	12
236	Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. <i>Vaccine</i> , 2016, 34, 5344-5351.	1.7	11
237	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. <i>PLoS Pathogens</i> , 2020, 16, e1008522.	2.1	11
238	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 678511.	2.2	11
239	Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection. <i>Npj Vaccines</i> , 2021, 6, 110.	2.9	11
240	Computational analysis of antibody dynamics identifies recent HIV-1 infection. <i>JCI Insight</i> , 2017, 2, .	2.3	11
241	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€³3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	1.9	11
242	Quality control, analysis and secure sharing of LuminexÂ® immunoassay data using the open source LabKey Server platform. <i>BMC Bioinformatics</i> , 2013, 14, 145.	1.2	10
243	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. <i>Vaccine Journal</i> , 2014, 21, 1589-1599.	3.2	10
244	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	1.5	10
245	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020, 10, 13031.	1.6	10
246	Tissue memory B cell repertoire analysis after ALVAC/AIDS VAX B/E gp120 immunization of rhesus macaques. <i>JCI Insight</i> , 2016, 1, e88522.	2.3	10
247	Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. <i>Vaccine</i> , 2017, 35, 1184-1193.	1.7	9
248	Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 233-246.	1.6	9
249	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	8
250	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. <i>Frontiers in Big Data</i> , 2021, 4, 672460.	1.8	8
251	Magnitude, Specificity, and Avidity of Sporozoite-Specific Antibodies Associate With Protection Status and Distinguish Among RTS,S/AS01 Dose Regimens. <i>Open Forum Infectious Diseases</i> , 2021, 8, .	0.4	8
252	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	3.9	8

#	ARTICLE	IF	CITATIONS
253	Changes in Circulating B Cell Subsets Associated with Aging and Acute SIV Infection in Rhesus Macaques. <i>PLoS ONE</i> , 2017, 12, e0170154.	1.1	8
254	Initiation of Human Immunodeficiency Virus Type 1 (HIV-1) Transcription is Inhibited by Noncytolytic CD8+ Suppression. <i>The Open Virology Journal</i> , 2007, 1, 1-7.	1.8	8
255	Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2014, 20, 583-585.	15.2	7
256	High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted <i>Mycobacterium tuberculosis</i> epitopes. <i>Scientific Reports</i> , 2014, 4, 4632.	1.6	7
257	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. <i>Journal of Immunology</i> , 2017, 198, 1047-1055.	0.4	7
258	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. <i>Scientific Reports</i> , 2019, 9, 10165.	1.6	7
259	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. <i>Journal of Infectious Diseases</i> , 2019, 219, 1755-1765.	1.9	7
260	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021, 6, 56.	2.9	7
261	<i>Salmonella</i> Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses. <i>Science Immunology</i> , 2021, 6, eabj1181.	5.6	7
262	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. <i>Journal of Virology</i> , 2021, , JVI0164321.	1.5	7
263	Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. <i>Journal of Virology</i> , 2021, 95, .	1.5	6
264	Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies. <i>Cell Reports</i> , 2022, 38, 110436.	2.9	6
265	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	5
266	RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines. <i>Scientific Reports</i> , 2020, 10, 14056.	1.6	4
267	A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities. <i>Journal of Virology</i> , 2020, 94, .	1.5	4
268	Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. <i>Frontiers in Immunology</i> , 2021, 12, 709994.	2.2	4
269	Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges. <i>Frontiers in Immunology</i> , 2022, 13, 788619.	2.2	4
270	Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, , .	1.1	4

#	ARTICLE	IF	CITATIONS
271	Kernel-based logistic regression model for protein sequence without vectorialization. <i>Biostatistics</i> , 2015, 16, 480-492.	0.9	3
272	Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaques. <i>Nature Communications</i> , 2019, 10, 3753.	5.8	3
273	Breadth of Human Monoclonal Antibodies Isolated from RTS,S/AS01 Vaccinees Binding to Plasmodium falciparum Circumsporozoite Protein Antigens. <i>Biophysical Journal</i> , 2019, 116, 480a.	0.2	3
274	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , 2020, 5, .	1.3	3
275	Titration analysis: A Tool for High-throughput Analysis of Binding Kinetics Data for Multiple Label-Free Platforms. <i>Biophysical Journal</i> , 2021, 120, 265a-266a.	0.2	3
276	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. <i>Vaccine</i> , 2021, 39, 3879-3891.	1.7	3
277	Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. <i>Frontiers in Immunology</i> , 2021, 12, 670561.	2.2	3
278	A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence. <i>PLoS Pathogens</i> , 2022, 18, e1010488.	2.1	3
279	142 HIV Frequently Elicits Mucosal and Plasma Env-Specific IgA With a Rapid Initial Decline In Acute Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, .	0.9	2
280	Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination. <i>Vaccine</i> , 2020, 38, 1678-1689.	1.7	2
281	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009624.	2.1	2
282	HIV-1/SIV Humoral Responses in External Secretions. <i>Current Immunology Reviews</i> , 2019, 15, 49-62.	1.2	2
283	Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV. <i>Npj Vaccines</i> , 2022, 7, 18.	2.9	2
284	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX [®] B/E in RV144 Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A36-A36.	0.5	1
285	Spectrum of HIV antibodies in vaccine and disease. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 207-209.	1.5	1
286	CD8+ T cells. <i>Aids</i> , 2018, 32, 2835-2838.	1.0	1
287	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. <i>Statistical Methods in Medical Research</i> , 2020, 29, 78-93.	0.7	1
288	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. <i>Vaccine</i> , 2021, 39, 4641-4650.	1.7	1

#	ARTICLE	IF	CITATIONS
289	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. <i>Frontiers in Immunology</i> , 2021, 12, 787603.	2.2	1
290	DNA and Protein Co-immunization Improves the Magnitude, Longevity, and Mucosal Dissemination of Immune Responses. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A63-A64.	0.5	0
291	Four-parameter paired response curve for serial dilution assays. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, 1-16.	0.4	0
292	Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases. <i>Vaccine</i> , 2021, 39, 5233-5239.	1.7	0